Citations

Clear

1575 citation(s) found for "Im, Gene".

Granulomatous Inflammation
Hilhorst, Marc , Hunder, Gene G. , Weyand, Cornelia M. , Goronzy, Jörg J.

Mayo Clinic

Inflammation | April 10, 2018 | Volume: No volume available | Issue: No issue available | Pages: 303-356

10.1142/9789813109445_0008 Get It

Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET
Stonnington, Cynthia M. , Chen, Yinghua , Savage, Cary R. , Lee, Wendy , Bauer, Robert, Sharieff, Sameen, Alexander, Gene E. , Caselli, Richard J. , Reiman, Eric M. , Locke, Dona E.C. , Thiyyagura, Pradeep , Chen, Kewei

Mayo Clinic

Journal of Alzheimer’s Disease | April 6, 2018 | Volume: 63 | Issue: 2 | Pages: 603-615

10.3233/jad-170852 | PMID 29630550 Get It

Background: Brain imaging measurements can provide evidence of possible preclinical Alzheimer’s disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. Objective: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. Methods: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. Results: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual’s imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). Conclusion: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
Phenotypic Variability of c.436delC DCAF17 Gene Mutation in Woodhouse-Sakati Syndrome
Almeqdadi, Mohammad , Kemppainen, Jennifer L., Pichurin, Pavel N. , Gavrilova, Ralitza H.

Mayo Clinic

American Journal of Case Reports | March 25, 2018 | Volume: 19 | Issue: No issue available | Pages: 347-353

10.12659/ajcr.907395 | PMID 29574468 Get It

Lightweight, compact, and high‐performance 3T MR system for imaging the brain and extremities
Foo, Thomas , Laskaris, E.T., Vermilyea, Mark, Xu, Minfeng , Thompson, Paul, Conte, Gene, Epps, Christopher Van, Immer, Christopher, Tan, Ek T. , Graziani, Dominic, Mathieu, Jean‐Baptise, Hardy, Christopher J., Schenck, John F., Fiveland, Eric, Stautner, Wolfgang , Ricci, Justin, Piel, Joseph E., Park, Keith, Hua, Yihe , Bai, Ye , Kagan, Alex, Stanley, David A. , Weavers, Paul T., Gray, Erin M. , Shu, Yunhong , Frick, Matthew A., Trzasko, Joshua D. , Foo, Thomas K F , Tan, Ek T , Gray, Erin, Trzasko, Joshua, Bernstein, Matt A , Thompson, Paul, Epps, Chris Van, Lee, Seung‐Kyun , Campeau, Norbert G. , Huston, John , Bernstein, Matt A.

Mayo Clinic

Magnetic Resonance in Medicine | March 15, 2018 | Volume: 80 | Issue: 5 | Pages: 2232-2245

10.1002/mrm.27175 | PMID 29536587 Get It

PurposeTo build and evaluate a small‐footprint, lightweight, high‐performance 3T MRI scanner for advanced brain imaging with image quality that is equal to or better than conventional whole‐body clinical 3T MRI scanners, while achieving substantial reductions in installation costs.MethodsA conduction‐cooled magnet was developed that uses less than 12 liters of liquid helium in a gas‐charged sealed system, and standard NbTi wire, and weighs approximately 2000 kg. A 42‐cm inner‐diameter gradient coil with asymmetric transverse axes was developed to provide patient access for head and extremity exams, while minimizing magnet‐gradient interactions that adversely affect image quality. The gradient coil was designed to achieve simultaneous operation of 80‐mT/m peak gradient amplitude at a slew rate of 700 T/m/s on each gradient axis using readily available 1‐MVA gradient drivers.ResultsIn a comparison of anatomical imaging in 16 patients using T2‐weighted 3D fluid‐attenuated inversion recovery (FLAIR) between the compact 3T and whole‐body 3T, image quality was assessed as equivalent to or better across several metrics. The ability to fully use a high slew rate of 700 T/m/s simultaneously with 80‐mT/m maximum gradient amplitude resulted in improvements in image quality across EPI, DWI, and anatomical imaging of the brain.ConclusionsThe compact 3T MRI system has been in continuous operation at the Mayo Clinic since March 2016. To date, over 200 patient studies have been completed, including 96 comparison studies with a clinical 3T whole‐body MRI. The increased gradient performance has reliably resulted in consistently improved image quality.
Visualizing Gene Expression in Real-Time
Carmichael, Stephen W.

Mayo Clinic

Microscopy Today | March 14, 2018 | Volume: 13 | Issue: 3 | Pages: 3-7

10.1017/s1551929500051567 Get It

Abstract Gene expression has been visualized for a few decades, but in static forms such as blots and gene chips. Susan Janicki, Toshiro Tsukamoto, Sim one Salghetti, William Tansey, Ravi Sachidanandam, Kannanganattu Prasanth, Thomas Ried, Yaron Shav-Tal, Edouard Bertrand, Robert Singer, and David Spector have recently designed a cell line in which gene expression can be observed with stunningly accurate spatial and temporal resolution. Gene expression is a cascade of events beginning with transcription of RNA from the DNA template and ending with translation into a protein sequence. Janicki et al. were able to visualize the entire process at the levels of DNA, RNA, and proteins in living cells!
Systematic Bias Introduced by Genomic DNA Template Dilution in 16S rRNA Gene-Targeted Microbiota Profiling in Human Stool Homogenates
Harrington, Sean C., Jeraldo, Patricio , Johnson, Stephen , Walther-António, Marina , Multinu, Francesco , Jeraldo, Patricio R , Chia, Nicholas , Walther-Antonio, Marina R, Walther-Antonio, Marina , Chen, Jun, Chia, Nicholas

Mayo Clinic

mSphere | March 13, 2018 | Volume: 3 | Issue: 2 | Pages: No page available

10.1128/msphere.00560-17 | PMID 29564398 Get It

The genomic DNA input for stool samples utilized for microbiome composition has not been determined. In this study, we determined the reliable threshold level under which conclusions drawn from the data may be compromised. We also determined the type of microbial bias introduced by less-than-ideal genomic input.
Predicted Arabidopsis Interactome Resource and Gene Set Linkage Analysis: A Transcriptomic Analysis Resource
Yao, Heng , Wang, Xiaoxuan , Chen, Pengcheng , Jin, Kang , Yao, Lixia , Mao, Chuanzao , Chen, Xin , Jin, Kang , Yao, Lixia , Mao, Chuanzao , Chen, Xin , Hai, Ling

Mayo Clinic

Plant Physiology | March 12, 2018 | Volume: 177 | Issue: 1 | Pages: 422-433

10.1104/pp.18.00144 | PMID 29530937 Get It

Genome Projects and Gene Therapy: Gateways to Next Generation Biological Weapons
Black, John L.

Mayo Clinic

Military Medicine | February 28, 2018 | Volume: 168 | Issue: 11 | Pages: 864-871

10.1093/milmed/168.11.864 Get It

Use of the CRISPR/Cas9‐based epigenetic gene activation system In Vivo: A new potential therapeutic modality
Ibrahim, Samar H. , Robertson, Keith D. , Robertson, Keith D , Ibrahim, Samar H

Mayo Clinic

Hepatology | February 28, 2018 | Volume: 68 | Issue: 3 | Pages: 1191-1193

10.1002/hep.29860 | PMID 29489018 Get It

Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study
Chedid, Victor , Vijayvargiya, Prakhar , Carlson, Paula, Malderen, Kathleen Van , Zinsmeister, Alan R., Camilleri, Michael , Camilleri, M , Chedid, Victor G , Acosta, Andrés

Mayo Clinic

Neurogastroenterology & Motility | February 28, 2018 | Volume: 30 | Issue: 7 | Pages: No page available

10.1111/nmo.13313 | PMID 29488276 Get It

AbstractBackgroundWeight loss in response to the long‐acting GLP‐1 receptor (GLP1R) analog, liraglutide, is correlated with delay in gastric‐emptying (GE). The aim of this pilot study was to assess whether specific genetic variants in GLP1R or TCF7L2 are associated with delayed GE and weight loss in obese patients treated with liraglutide or the short‐acting GLP‐1 agonist, exenatide.MethodsWe evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks. Data were analyzed using the dominant genetic model and intention‐to‐treat analysis.Key ResultsThere was a significant correlation between changes in weight and GE T1/2 (rs = −.382, P = .004). GLP1R rs6923761 minor allele A (AA_AG) carriers who received either exenatide or liraglutide had greater delay in GE T1/2 relative to baseline (117.9 ± 27.5 [SEM] minutes and 128.9 ± 38.32 minutes) compared to GG genotype (95.8 ± 30.4 minutes and 61.4 ± 21.4 minutes, respectively; P = .11). There was a non‐significant difference in weight loss based on GLP1R rs6923761 genotype after 5 weeks of treatment. There were no significant correlations with TCF7L2 (rs7903146) genotype.Conclusions & InferencesThe minor A allele of GLP1R (rs6923761) is associated with greater delay in GE T1/2 in response to liraglutide and exenatide. These studies provide data to plan pharmacogenetics testing of the hypothesis that GLP1R (rs6923761) influences weight loss in response to GLP1R agonists.